No Data
[IPO Monthly Report] The hot market for Hong Kong IPOs in October remains unabated. The oversubscription ratio of Karotex was 1346 times, and China Resources Beverage may become the "capital freezing king" of the year.
In September, Midea Group Co., Ltd. (00300) raised 35.7 billion yuan, becoming the largest in the Hong Kong stock market since February 2021, the largest in Asia in the first three quarters of 2024, and the second largest in the world by 2024. The Chief Executive Officer of HKEX, Bonnie Chan Yi-Ting, stated: "Recently, the HKEX welcomed the largest in Asia and the second largest in the world in terms of new stock listings this year. Refinancing activities are also very active, demonstrating the depth and attractiveness of our market. The number of new stock listing applications further consolidates Hong Kong's position as the preferred new stock fundraising center in Asia. In addition, Alibaba has converted to a dual primary listing and was subsequently included in the Stock Connect."
After boosting its stock price by 30% through the 'routine callback', what is supporting Huahao Zhongtian Pharmaceutical-B (02563) to sustain a market cap of nearly 8 billion Hong Kong dollars?
In short, the weak profit performance and the research and development department relying solely on a single core product make Huahao Zhongtian Pharmaceuticals face a certain degree of uncertainty in future performance. In addition, the poor performance of the synthetic biology track on the secondary market globally means that Huahao Zhongtian Pharmaceuticals needs to continuously optimize its own fundamentals to prove itself in the Hong Kong stock market, while enhancing its innovation and further strengthening its own hematopoietic capacity.
New stock first day | Huahao Zhongtian Medicine-B (02563) first listed on the market, opening high in the morning by 34.38%.
Huahao Zhongtian Pharmaceutical-B (02563) made its debut on the stock market. The announcement shows that the price per share is 16 Hong Kong dollars, with a total issuance of 14.588 million shares, and 200 shares per lot. The net proceeds from the offering are expected to be approximately 0.19589 billion Hong Kong dollars. As of the time of this report, it has risen by 34.38%, trading at 21.5 Hong Kong dollars, with a turnover of 22.4505 million Hong Kong dollars.
Huahao Zhongtian Pharmaceutical-B (02563) is priced at a maximum of 21.45 times the public offering subscription.
Huahao Zhongtian Pharmaceutical-B (02563) announced the results of the distribution. The company plans to globally issue 14.588 million shares of stock, public...
New stock dark horse | Huahao Zhongtian Medicine-B (02563) dark horse plate initial rise exceeds 23%, earning 760 Hong Kong dollars per lot.
HuaHao ZhongTian Medicine-B (02563) will be listed in Hong Kong on October 31st (Thursday).
New stock analysis | The public offering of shares has met with a cold response. Why is Huahao Zhongtian Medical-B (02563) not favored by the market?
After years on the market, the core product has still not escaped losses. What should Hua Hao Zhong Tian Pharmaceuticals-B (02563) do next?
